SAN DIEGO, CA, October 4, 2011 — OncoSec Medical Incorporated (OTCBB: ONCS), which is developing its advanced-stage OMS ElectroOncology™ therapies to treat solid tumor cancers, announced today that Punit Dhillon, President and CEO, will be presenting at the 2nd Annual “Cancer Immunotherapy: A Long-Awaited Reality” Conference in New York, New York.
2nd Annual “Cancer Immunotherapy: A Long-Awaited Reality”
New York Academy of Medicine
1216 5th Avenue
New York, New York 10029
October 6, 2011
4:30 pm ET
A live and archived webcast will be accessible on OncoSec’s website www.oncosec.com
This unique, single-day conference event unites founding visionary researchers, clinicians, business leaders, key investors, and other stakeholders to engage in discussions, exchange information, highlight opportunities, and showcase leading companies in the field of cancer immunotherapy.
OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapies have achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials. More information is available at www.oncosec.com.